Every 8-K that Veradermics, Incorporated (MANE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MANE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MANE filings page.
Veradermics, Incorporated reported second quarter 2026 results and clinical progress for its lead candidate VDPHL01, an extended-release oral minoxidil in Phase 3 development for pattern hair loss. Positive topline data from open-label Phase 2 Study ‘207’ in women showed mean increases in non-vellus target area hair count of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6, with no treatment-related serious cardiac adverse events. Enrollment has been completed in the 556-participant Phase 2/3 registration-directed Study ‘306’ in women, with topline data expected in the first half of 2027, and additional data from male Studies ‘302’ and ‘304’ anticipated in the second half of 2026.
Cash, cash equivalents and marketable securities totaled $819.9 million as of June 30, 2026, supported by approximately $472.0 million in gross proceeds from a May 2026 follow-on offering and concurrent private placement, which the company expects will fund operations into 2030, including multiple Phase 3 readouts and potential launch of VDPHL01, if approved. For the quarter, research and development expenses were $18.6 million, general and administrative expenses were $10.9 million, and net loss was $23.5 million, compared with a net loss of $15.6 million in the prior-year quarter.
Veradermics, Incorporated reported positive topline Phase 2 data from Study ‘207’ of VDPHL01, an extended-release oral minoxidil tablet, in women with mild-to-moderate pattern hair loss. Female participants receiving 4.5 mg once or twice daily for 6 months showed objective hair growth and high patient-reported benefit.
Average non-vellus Target Area Hair Count increased 22.7 hairs/cm² in the once-daily arm and 23.3 hairs/cm² in the twice-daily arm at Month 6. On the Androgenetic Alopecia Impact Rating Scale, 88.9% (once-daily) and 90.0% (twice-daily) of women reported ‘improved’ or ‘much improved’ hair coverage, while investigators graded 100% and 90% of participants, respectively, as improved. Improvement was already seen at Month 2, with investigators and patients reporting benefits in 67.2% and 63.2% of participants.
VDPHL01 was generally well tolerated through Month 6, with no treatment-related serious adverse events and no cardiac adverse events of special interest; the most common adverse events were hypertrichosis and peripheral edema. Veradermics is running registration-directed Phase 2/3 trials in male and female pattern hair loss, with key topline readouts expected in 2026–2027.
Veradermics, Inc. reported a larger net loss for the first quarter of 2026 as it accelerated late-stage development of its lead hair-loss drug VDPHL01 and strengthened its balance sheet. Net loss was $27.2 million, compared with $12.4 million a year earlier, driven by higher R&D and G&A spending.
Cash, cash equivalents and marketable securities were $390.8 million as of March 31, 2026, reflecting proceeds from an upsized IPO in February. A follow-on offering completed after quarter-end raised an additional $472.0 million in gross proceeds, contributing to an aggregate $766.8 million raised in 2026 and a projected cash runway into 2030.
The company highlighted positive topline results from Part A of Phase 2/3 Study ‘302’ of oral, extended-release minoxidil tablet VDPHL01 in male pattern hair loss, completion of enrollment in confirmatory Phase 3 Study ‘304’, and ongoing enrollment in Phase 2/3 Study ‘306’ in women, positioning VDPHL01 as a potential first-in-class non-hormonal oral treatment.
Veradermics, Incorporated completed an underwritten public offering of 3,843,790 shares of common stock at $100.00 per share, using its effective Form S-1 registration statements. The underwriters also received a 30-day option to buy up to an additional 576,568 shares at the same public price, less fees.
At the same time, Veradermics closed a private placement of pre-funded warrants to Suvretta Capital–affiliated investors, covering 300,000 shares of common stock at $99.99999 per warrant, for gross proceeds of about $30.0 million before costs. Each pre-funded warrant carries a nominal exercise price of $0.00001 per share, can be exercised in cash or cashlessly, and remains outstanding until fully exercised.
The warrants include a beneficial ownership limitation that blocks exercises above 9.99% of Veradermics’ common stock, with the ability for a holder to adjust the cap up to 19.99% effective on the 61st day after notice. The company agreed to customary covenants in the Securities Purchase Agreement, including restrictions on additional equity issuances for 90 days, subject to exceptions.
Veradermics, Incorporated reports a preliminary unaudited balance of cash, cash equivalents and marketable securities of about $390.8 million as of March 31, 2026.
The figure was prepared by management and is subject to the company’s normal financial closing procedures, so the final amount in the unaudited condensed consolidated financial statements for the three months ended March 31, 2026 may differ materially. The company notes that Deloitte & Touche LLP has not audited, reviewed, examined, compiled or applied agreed-upon procedures to this preliminary data and therefore does not provide any assurance on it.
Veradermics, Inc. reported positive topline results from its Phase 2/3 Study ‘302’ of oral VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The trial met all primary and key secondary endpoints, with once-daily and twice-daily doses showing significantly greater hair growth than placebo.
At Month 6, non‑vellus target area hair count increased by 30.3 hairs/cm² with once-daily VDPHL01 and 33.0 hairs/cm² with twice-daily dosing, versus 7.3 hairs/cm² for placebo. Patient-reported ‘improved’ or ‘much improved’ outcomes reached 48.4% and 62.9% in the active arms compared with 13.4% on placebo.
Any improvement in hair coverage was reported by 79.3% and 86.0% of VDPHL01 patients versus 35.6% on placebo, and investigators graded 72.0% and 84.4% of active-arm patients as improved. VDPHL01 was generally well tolerated, with no treatment-related serious adverse events or cardiac adverse events of special interest and treatment-emergent adverse event rates similar to placebo.
Veradermics, Inc. reported a larger net loss for the fourth quarter and full year 2025 as it accelerated late-stage development of its oral hair-loss candidate VDPHL01 and prepared to go public. Net loss was $21.8 million for the quarter and $70.0 million for 2025, compared with $5.7 million and $26.5 million in 2024.
Research and development spending more than doubled to $62.1 million in 2025, and general and administrative costs also rose as the company scaled its organization. Cash, cash equivalents and marketable securities were $141.9 million at December 31, 2025, before an upsized IPO in February 2026 that raised approximately $294.8 million in gross proceeds, which the company expects will fund operations into 2029, including multiple Phase 3 readouts and a potential launch of VDPHL01 if approved.
Veradermics, Incorporated updated its corporate charter and bylaws on February 5, 2026 in connection with the consummation of its initial public offering of common stock. A fifth restated certificate of incorporation became effective upon filing with the Delaware Secretary of State.
The Restated Certificate authorizes 200 million shares of common stock and 25 million shares of undesignated preferred stock, eliminates all prior preferred series, and removes stockholders’ ability to act by written consent. Amended and restated bylaws also took effect, refining stockholder proposal and director nomination procedures, updating director and officer indemnification, and aligning with the new charter provisions.